Screener / SEC EDGAR /CIK 0001321732 /10-K filed Feb 25, 2026, compared with Feb 18, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Penumbra Inc PEN

Compare with peers Embed
FY2025 at a glance

Sales up 17.5%, free cash flow up to $174.9M

XBRL, from each 10-K
RevenueStatements
$1.4B from $1.2B in FY2024
FY2016FY2025
Net incomeStatements
$177.7M from $14.0M in FY2024
FY2016FY2025
Free cash flowStatements
$174.9M from $147.3M in FY2024
FY2016FY2025
EPS (diluted)Statements
$4.52 from $0.36 in FY2024
FY2016FY2025
Operating marginStatements
13.5% from 0.8% in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (41)
EPS (ttm)
3.97
Sales (ttm)
1.6B
Net income (ttm)
157.0M
Sales growth
+17.5%
EPS growth
n/m
Sales Q/Q
+15.6%
Free cash flow
200.3M
Gross margin
68.0%
Oper. margin
12.1%
Net margin
10.1%
FCF margin
12.8%
ROE
9.9%
ROA
7.8%
R&D / sales
6.4%
Dividend
-
Debt/Eq
-
Curr. ratio
5.89
Cash
254.3M
Op. cash flow (ttm)
261.0M
EBITDA
206.7M
EBITDA margin
14.7%
Quick ratio
4.04
Interest cover
144.35
ROIC
10.4%
FCF after stock pay
115.7M
Goodwill / assets
9.1%
Oper. margin low 5y
-1.0%
Tax rate
13.4%
Stock pay / sales
4.2%
Shares out.
39.4M
Shares Y/Y
+0.1%
Book / share
40.18
Cash / share
6.45
Sales / share
39.59
Asset turnover
0.77
Inventory turns
1.07
Days sales out.
49
Sales 3Y CAGR
+18.3%
Sales 5Y CAGR
+20.2%
Employees
4,700
Sales / employee
332K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 1.4B +20.4% a year Net income 177.7M +31.8% a year
FY2016 revenue 263.3M · Revenues, 0001321732-19-000031 FY2016 net income 14.8M · NetIncomeLoss, 0001321732-19-000031 263.3M FY2016 FY2017 revenue 333.8M · Revenues, 0001321732-20-000047 FY2017 net income 4.7M · NetIncomeLoss, 0001321732-20-000047 333.8M FY2017 FY2018 revenue 444.9M · Revenues, 0001628280-21-002867 FY2018 net income 6.6M · NetIncomeLoss, 0001628280-21-002867 444.9M FY2018 FY2019 revenue 547.4M · Revenues, 0001321732-22-000017 FY2019 net income 48.5M · NetIncomeLoss, 0001321732-22-000017 547.4M FY2019 FY2020 revenue 560.4M · Revenues, 0001321732-23-000034 FY2020 net income -15.7M · NetIncomeLoss, 0001321732-23-000034 560.4M FY2020 FY2021 revenue 747.6M · Revenues, 0001321732-24-000025 FY2021 net income 5.3M · NetIncomeLoss, 0001321732-24-000025 747.6M FY2021 FY2022 revenue 847.1M · Revenues, 0001321732-25-000012 FY2022 net income -2.0M · NetIncomeLoss, 0001321732-25-000012 847.1M FY2022 FY2023 revenue 1.1B · Revenues, 0001321732-26-000007 FY2023 net income 91.0M · NetIncomeLoss, 0001321732-26-000007 1.1B FY2023 FY2024 revenue 1.2B · Revenues, 0001321732-26-000007 FY2024 net income 14.0M · NetIncomeLoss, 0001321732-26-000007 1.2B FY2024 FY2025 revenue 1.4B · Revenues, 0001321732-26-000007 FY2025 net income 177.7M · NetIncomeLoss, 0001321732-26-000007 1.4B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Earnings per share +49.7% a year FY2015 $0.08 to FY2025 $4.52, 10 years
Book value per share +8.3% a year FY2015 $16.35 to FY2025 $36.33, 10 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $4.52$36.33$4.45
Dec 31, 2024 $0.36$29.31$3.75
Dec 31, 2023 $2.32$30.06$2.09
Dec 31, 2022 -$0.05$26.40-$1.98
Dec 31, 2021 $0.14$25.18-$0.31
Dec 31, 2020 -$0.44$17.94-$1.62
Dec 31, 2019 $1.34$13.40$0.13
Dec 31, 2018 $0.18$11.70$0.53
Dec 31, 2017 $0.13$11.34$0.00
Dec 31, 2016 $0.44$7.96-$0.79
Dec 31, 2015 $0.08$16.35-$1.84

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $1.2B
  • − All liabilities $398.9M
  • = Net current asset value $817.8M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $1.4B
  • − Goodwill $166.8M
  • − Other intangible assets $6.2M
  • = Tangible book value $1.3B
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

PEN against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+17.5%46th of 155 · median +10.5%
Net margin
-4.1%15.3%
10.1%61st of 154 · median 6.8%
Return on equity
-5.2%18.5%
9.9%68th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
12.8%62nd of 145 · median 10.0%
PEN and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
PEN Penumbra Inc$1.6B +17.5%68.0%10.1%9.9%12.8%-
MMSI Merit Medical Systems Inc$1.6B +11.8%49.4%9.9%9.2%12.6%0.42
LNTH Lantheus Holdings, Inc.$1.6B +0.5%61.3%17.3%19.9%-0.42
INSM INSMED Inc$1.5B +66.7%84.4%-39.9%-83.4%-41.3%0.75
LIVN LivaNova PLC$1.5B +10.7%67.8%13.0%14.3%8.6%0.22
ADUS Addus HomeCare Corp$1.5B +23.2%32.3%7.4%9.4%9.6%0.02
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by product

From $747.6M of sales to $5.3M of profit FY2021

  • Thrombectomy $437.8M
  • Embolization and Other $309.8M
Revenue to Gross profit: $475.4MRevenue to Cost of revenue: $272.2MGross profit to Net profit: $5.3MGross profit to Costs, tax, other: $470.1M Revenue: $747.6M REVENUE $747.6M +33% Y/Y Gross profit: $475.4M · 64% margin GROSS PROFIT $475.4M 64% margin · +41% Y/Y Cost of revenue: $272.2M · 36% of revenue COST OF REVENUE $272.2M 36% of revenue Net profit: $5.3M · 1% margin NET PROFIT $5.3M 1% margin Costs, tax, other: $470.1M · 63% of revenue COSTS, TAX, OTHER $470.1M 63% of revenue

From $1.1B of sales to $91.0M of profit FY2023

  • Thrombectomy $677.3M
  • Embolization and Other $381.2M
Revenue to Gross profit: $682.6MRevenue to Cost of revenue: $375.9MGross profit to Operating profit: $73.6MGross profit to Operating expenses: $609.1MOperating profit to Net profit: $73.6MOther income to Net profit: $17.4MOperating expenses to R&D: $84.4MOperating expenses to Sales, admin & other: $524.7M Revenue: $1.1B REVENUE $1.1B +25% Y/Y Gross profit: $682.6M · 64% margin GROSS PROFIT $682.6M 64% margin · +28% Y/Y Cost of revenue: $375.9M · 36% of revenue COST OF REVENUE $375.9M 36% of revenue Operating profit: $73.6M · 7% margin OPERATING PROFIT $73.6M 7% margin · +1109% Y/Y Other income: $17.4M · 2% of revenue OTHER INCOME $17.4M 2% of revenue Operating expenses: $609.1M · 58% of revenue OPERATING EXPENSES $609.1M 58% of revenue Net profit: $91.0M · 9% margin NET PROFIT $91.0M 9% margin R&D: $84.4M · 8% of revenue R&D $84.4M 8% of revenue Sales, admin & other: $524.7M · 50% of revenue SALES, ADMIN & OTHER $524.7M 50% of revenue

From $1.2B of sales to $14.0M of profit FY2024

  • Thrombectomy $815.5M
  • Embolization and Other $379.1M
Revenue to Gross profit: $755.0MRevenue to Cost of revenue: $439.6MGross profit to Operating profit: $9.3MGross profit to Operating expenses: $745.7MOperating profit to Net profit: $2.4MOperating profit to Tax: $6.9MOther income to Net profit: $11.6MOperating expenses to R&D: $94.8MOperating expenses to Sales, admin & other: $650.9M Revenue: $1.2B REVENUE $1.2B +13% Y/Y Gross profit: $755.0M · 63% margin GROSS PROFIT $755.0M 63% margin · +11% Y/Y Cost of revenue: $439.6M · 37% of revenue COST OF REVENUE $439.6M 37% of revenue Operating profit: $9.3M · 1% margin OPERATING PROFIT $9.3M 1% margin · −87% Y/Y Other income: $11.6M · 1% of revenue OTHER INCOME $11.6M 1% of revenue Operating expenses: $745.7M · 62% of revenue OPERATING EXPENSES $745.7M 62% of revenue Net profit: $14.0M · 1% margin NET PROFIT $14.0M 1% margin · −85% Y/Y Tax: $6.9M · 1% of revenue TAX $6.9M 1% of revenue R&D: $94.8M · 8% of revenue R&D $94.8M 8% of revenue Sales, admin & other: $650.9M · 54% of revenue SALES, ADMIN & OTHER $650.9M 54% of revenue

From $1.4B of sales to $177.7M of profit FY2025

  • Thrombectomy $947.9M
  • Embolization and Other $455.7M
Revenue to Gross profit: $942.4MRevenue to Cost of revenue: $461.2MGross profit to Operating profit: $189.2MGross profit to Operating expenses: $753.2MOperating profit to Net profit: $161.8MOperating profit to Tax: $27.4MOther income to Net profit: $15.9MOperating expenses to R&D: $89.8MOperating expenses to SG&A: $663.4M Revenue: $1.4B REVENUE $1.4B +17% Y/Y Gross profit: $942.4M · 67% margin GROSS PROFIT $942.4M 67% margin · +25% Y/Y Cost of revenue: $461.2M · 33% of revenue COST OF REVENUE $461.2M 33% of revenue Operating profit: $189.2M · 13% margin OPERATING PROFIT $189.2M 13% margin · +1940% Y/Y Other income: $15.9M · 1% of revenue OTHER INCOME $15.9M 1% of revenue Operating expenses: $753.2M · 54% of revenue OPERATING EXPENSES $753.2M 54% of revenue Net profit: $177.7M · 13% margin NET PROFIT $177.7M 13% margin · +1168% Y/Y Tax: $27.4M · 2% of revenue TAX $27.4M 2% of revenue R&D: $89.8M · 6% of revenue R&D $89.8M 6% of revenue SG&A: $663.4M · 47% of revenue SG&A $663.4M 47% of revenue

Where each $100 of sales went

FY2021
FY2023
FY2024
FY2025
  • Cost of revenue
  • Sales, admin & other
  • Net profit
  • R&D
  • Tax, less other income

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 12.4% FY2020: -2.4% net income ÷ equity
Net margin 12.7% FY2020: -2.8% profit per $ of sales: 177.7M ÷ 1.4B
Asset turnover 0.77× FY2020: 0.68× sales per $ of assets: 1.4B ÷ 1.8B
Leverage 1.28× FY2020: 1.28× assets per $ of equity: 1.8B ÷ 1.4B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin above the peer median
    10.1% vs 6.8%
  • Gross margin up over 5 years
    60.3% → 67.1%
  • Return on equity below 15%
    9.9%
  • A profit in 8 of 10 years
Net margin, FY2016 to FY2025: 5.6% to 12.7%

Balance sheet

  • Interest covered more than 5 times
    Operating income is over 100× interest expense
  • Current assets cover current liabilities
    Current ratio 5.89

Cash and shareholders

  • Free cash flow positive in 6 of 10 years
    $174.9M last year
  • Share count up over 5 years
    +9.9%
  • Cash from operations above net income
    $238.7M vs $177.7M
Free cash flow, FY2016 to FY2025: -26.4M to 174.9M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

PEN's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue1.4B
FY2016: 263.3MFY2017: 333.8MFY2018: 444.9MFY2019: 547.4MFY2020: 560.4MFY2021: 747.6MFY2022: 847.1MFY2023: 1.1BFY2024: 1.2BFY2025: 1.4B FY2017FY2019FY2021FY2023FY2025
Net income177.7M
FY2016: 14.8MFY2017: 4.7MFY2018: 6.6MFY2019: 48.5MFY2020: -15.7MFY2021: 5.3MFY2022: -2.0MFY2023: 91.0MFY2024: 14.0MFY2025: 177.7M FY2017FY2019FY2021FY2023FY2025
Free cash flow174.9M
FY2016: -26.4MFY2017: 159KFY2018: 19.2MFY2019: 4.5MFY2020: -58.0MFY2021: -11.7MFY2022: -75.0MFY2023: 82.1MFY2024: 147.3MFY2025: 174.9M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay115.7M
FY2016: -41.1MFY2017: -17.7MFY2018: 783KFY2019: -16.9MFY2020: -83.5MFY2021: -77.4MFY2022: -112.3MFY2023: 31.6MFY2024: 101.1MFY2025: 115.7M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)4.52
FY2016: 0.44FY2017: 0.13FY2018: 0.18FY2019: 1.34FY2020: -0.44FY2021: 0.14FY2022: -0.05FY2023: 2.32FY2024: 0.36FY2025: 4.52 FY2017FY2019FY2021FY2023FY2025
Diluted shares39.3M
FY2016: 33.5MFY2017: 35.3MFY2018: 36.1MFY2019: 36.3MFY2020: 35.8MFY2021: 37.9MFY2022: 37.8MFY2023: 39.2MFY2024: 39.3MFY2025: 39.3M FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Thrombectomy 947.9M67.5% +16.2%
Embolization and Other 455.7M32.5% +20.2%

10-K 0001321732-26-000007, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
United States 1.1B77.8% +21.0%
International 311.9M22.2% +6.6%

10-K 0001321732-26-000007, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue263.3M333.8M444.9M547.4M560.4M747.6M847.1M1.1B1.2B1.4B
Cost of revenue92.5M116.6M152.4M175.4M222.2M272.2M311.9M375.9M439.6M461.2M
Gross profit170.8M217.1M292.5M372.0M338.2M475.4M535.2M682.6M755.0M942.4M
R&D23.9M31.7M36.2M51.7M90.0M104.6M79.4M84.4M94.8M89.8M
SG&A148.3M184.3M226.4M272.7M287.1M378.3M449.7M506.5M574.0M663.4M
Operating income-1.4M1.2M-852K47.5M-38.9M-7.5M6.1M73.6M9.3M189.2M
Interest expense-----1.9M1.7M1.7M1.4M1.3M
Pretax income-869K2.5M1.6M50.1M-38.0M-10.5M3.9M79.7M20.9M205.1M
Income tax-15.7M-3.6M-4.4M3.1M-18.8M-13.1M5.9M-11.3M6.9M27.4M
Net income14.8M4.7M6.6M48.5M-15.7M5.3M-2.0M91.0M14.0M177.7M
EPS (diluted)0.440.130.181.34-0.440.14-0.052.320.364.52
Diluted shares33.5M35.3M36.1M36.3M35.8M37.9M37.8M39.2M39.3M39.3M
Depreciation & amortization2.3M3.8M6.2M8.1M12.9M16.4M24.3M27.3M23.7M17.5M
EBITDA947K4.9M5.3M55.6M-26.1M8.9M30.4M100.8M33.0M206.7M
Gross margin64.9%65.1%65.7%68.0%60.3%63.6%63.2%64.5%63.2%67.1%
Operating margin-0.5%0.3%-0.2%8.7%-6.9%-1.0%0.7%6.9%0.8%13.5%
Net margin5.6%1.4%1.5%8.9%-2.8%0.7%-0.2%8.6%1.2%12.7%
Revenue growth+41.5%+26.8%+33.3%+23.0%+2.4%+33.4%+13.3%+25.0%+12.9%+17.5%
EPS growth+450%-70.5%+38.5%+644%to a loss-to a loss--84.5%+1156%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-12.8M12.7M28.8M26.7M-33.2M9.5M-55.7M97.3M168.5M238.7M
Capital spending13.6M12.5M9.6M22.1M24.8M21.2M19.3M15.2M21.2M63.7M
Free cash flow-26.4M159K19.2M4.5M-58.0M-11.7M-75.0M82.1M147.3M174.9M
Stock-based pay (added back)14.6M17.8M18.4M21.5M25.5M65.8M37.4M50.5M46.2M59.2M
Free cash flow after stock pay-41.1M-17.7M783K-16.9M-83.5M-77.4M-112.3M31.6M101.1M115.7M
Buybacks------00100.4M0
Acquisitions09.3M20.4M00-----
Investing cash flow687K-77.7M-385K-12.7M-104.1M-21.7M54.8M-16.1M77.6M-404.6M
Financing cash flow7.1M104.4M-9.8M-9.0M134.9M836K11.6M16.2M-87.0M26.5M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)14.6M17.8M18.4M21.5M25.5M65.8M37.4M50.5M46.2M59.2M
Stock-based pay / revenue5.6%5.3%4.1%3.9%4.6%8.8%4.4%4.8%3.9%4.2%
Operating lease cost---7.3M7.6M11.6M20.3M23.0M23.5M24.1M
Operating lease cash paid---6.8M7.6M9.7M17.6M19.7M21.7M22.6M
Finance lease principal paid--02.6M3.4M1.5M1.8M2.0M2.3M2.5M
Right-of-use assets--043.7M41.2M132.0M192.6M188.8M177.8M173.6M
Operating lease liabilities--051.4M48.9M145.3M209.0M208.4M199.3M196.6M
Finance lease liabilities---30.9M28.4M28.2M26.8M25.9M24.1M23.1M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PEN/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.